CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 117 enrolled
Drug / intervention
Group 1 +2 moreprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02059512
NCT02059512N/ACompleted

Influence of the Administration of Autologous Bone Marrow Mononuclear Cells for the Duration of Functioning Aorto-coronary Bypass Grafts in the Surgical Treatment of Coronary Heart Disease

St. Petersburg State Pavlov Medical University·interventional·Posted Feb 11, 2014·Updated May 24, 2021

In Brief

A clinical study evaluating Group 1, Group 0, and 1 other intervention for Ischemic Heart Disease and 3 related conditions. Completed, enrolled 117 participants across 1 site.

Detailed Summary

The purpose of this study evaluate the effect of the method of administration of autologous bone marrow mononuclear cells for the duration of of functioning aorto-coronary bypass grafts in the surgical treatment of coronary heart disease, to assess the degree of effectiveness depending on the method of transplantation (intramyocardial, intracoronary, combined).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesRussia
Collaborators--

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedFeb 11, 2014
Enrollment StartFeb 1, 2013
Primary CompletionDec 1, 2016
Study CompletionJan 1, 2018
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 12.4 years ago

Interventions

Group 1procedure

Coronary artery bypass grafting with intramyocardial administration of autologous bone marrow mononuclear cells 0.2 ml - 10 injection in the zone of blood supply LAD.

Group 0procedure

Coronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD.

Group 2procedure

Coronary artery bypass grafting with intramyocardial and intracoronary administration of autologous bone marrow mononuclear cells intramyocardial administration 0.2 ml - 10 injection in the zone of blood supply LAD.